sur DocMorris AG (isin : CH0042615283)
DocMorris Reports Solid 11.1% Revenue Growth in 2025
DocMorris AG announced an increase in revenue by 11.1% in 2025, driven by strong performance in the fourth quarter. The Swiss online pharmacy reported a surge in digital services, highlighted by a 124% increase in TeleClinic revenue. The company's AI Health Companion saw significant adoption, with one-third of app users engaging with the AI assistant.
In Germany, DocMorris reported a 15.5% rise in external revenue during Q4. Prescription medication sales grew by 22.3% during the same period. Non-prescription revenue also displayed robust growth, fueled by both OTC sales and digital services.
Despite challenges such as the discontinuation of the Zur Rose brand, DocMorris successfully expanded its customer base to 11 million active customers by year-end. Going forward, the company forecasts achieving EBITDA breakeven in 2026.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de DocMorris AG